Preferred Cell Systems
Private Company
Funding information not available
Overview
Founded in 2015 and based in San Diego, Preferred Cell Systems operates as a specialized tools and reagents provider within the cell therapy and regenerative medicine ecosystem. The company's core business is manufacturing and distributing innovative in vitro assay kits and culture media, including its proprietary Keystone Assay™, which are used to assess cell quality and function for therapeutic applications. Unlike a therapeutic developer, PCS generates revenue by supplying the research tools necessary for drug and therapy development, partnering with contract research organizations like HemoGenix for services. Its strategic focus is on supporting the rapidly growing fields of cellular therapy and regenerative medicine with standardized, high-quality products.
Technology Platform
Portfolio of in vitro bioassays (bioluminescence, fluorescence, absorbance) and specialized cell culture media for characterizing cell health, potency, and toxicity in cellular therapy and regenerative medicine research.
Opportunities
Risk Factors
Competitive Landscape
PCS competes in the life sciences tools and reagents market, facing competition from giants like Thermo Fisher Scientific, Merck Millipore, and STEMCELL Technologies, as well as numerous niche players. Its differentiation is its specialized focus on functional assays for cell therapy QC and its exclusive products from the HemoGenix lineage.